Data / Drug companies / BSP Pharmaceuticals S.p.A.
BSP Pharmaceuticals S.p.A.: 44 products in the FDA NDC directory, labeler code 43624
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
BSP Pharmaceuticals S.p.A. (labeler code 43624) lists 44 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 43 drugs for further processing, 1 prescription drugs. Its main marketing category is drugs for further processing. The newest product started marketing on September 22, 2026.
The request: Watch BSP Pharmaceuticals S.p.A. (FDA labeler code 43624): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 43624
- Products in commercial distribution
- 44
- Packages
- 44
- Finished drugs by generic name
- 1
- Prescription products
- 1
- Over the counter products
- 0
- Flagged as original packager
- 1 of 1 products that carry the flag
- Started marketing in the last 12 months
- 9
- Earliest marketing start
- May 13, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 43 | 97.7% |
| New drug applications (NDA) | 1 | 2.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 43 | 97.7% |
| Prescription drugs | 1 | 2.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Eribulin mesylate | 1 | 17 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 17 | 38.6% |
| Injection, powder, lyophilized, for solution | 12 | 27.3% |
| Injection | 10 | 22.7% |
| Powder, for solution | 3 | 6.8% |
| Tablet, film coated | 1 | 2.3% |
| Tablet | 1 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Microtubule Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Donanemab | 43624-044 | Injection, solution | Drugs for further processing | September 22, 2026 |
| Pivekimab sunirine drug product (dp) | 43624-039 | Injection, powder, lyophilized, for solution | Drugs for further processing | May 29, 2026 |
| Trabectedin | 43624-046 | Injection, powder, lyophilized, for solution | Drugs for further processing | January 10, 2026 |
| Multiple-dose tirzepatide injection | 43624-038 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Multiple-dose tirzepatide injection | 43624-037 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Multiple-dose tirzepatide injection | 43624-036 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Multiple-dose tirzepatide injection | 43624-035 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Multiple-dose tirzepatide injection | 43624-034 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Multiple-dose tirzepatide injection | 43624-033 | Injection, solution | Drugs for further processing | November 30, 2025 |
| Pembrolizumab and berahyaluronidase alfa | 43624-031 | Injection, solution | Drugs for further processing | September 19, 2025 |
| Pembrolizumab and berahyaluronidase alfa | 43624-030 | Injection, solution | Drugs for further processing | September 19, 2025 |
| Tar-200 | 43624-032 | Tablet | Drugs for further processing | September 1, 2025 |
| Telisotuzumab vedotin | 43624-029 | Injection | Drugs for further processing | March 13, 2025 |
| Telisotuzumab vedotin | 43624-028 | Injection | Drugs for further processing | March 13, 2025 |
| Denileukin diftitox lyo 300 mcg/vial cit | 43624-027 | Injection | Drugs for further processing | June 24, 2024 |
| Enfortumab vedotin-ejfv for injection | 43624-023 | Injection | Drugs for further processing | January 5, 2024 |
| Enfortumab vedotin-ejfv for injection | 43624-014 | Injection | Drugs for further processing | January 5, 2024 |
| Cedazuridine and decitabine | 43624-022 | Tablet, film coated | Drugs for further processing | January 4, 2024 |
| Patritumab deruxtecan | 43624-021 | Injection, powder, lyophilized, for solution | Drugs for further processing | January 4, 2024 |
| Mitomycin | 43624-047 | Powder, for solution | Drugs for further processing | January 3, 2024 |
| Mirikizumab inj 300 mg/15 ml vial reform | 43624-026 | Injection | Drugs for further processing | October 26, 2023 |
| Mirikizumab inj 300 mg/15ml vial | 43624-025 | Injection | Drugs for further processing | October 26, 2023 |
| Tirzepatide | 43624-020 | Injection, solution | Drugs for further processing | August 1, 2023 |
| Tirzepatide | 43624-019 | Injection, solution | Drugs for further processing | August 1, 2023 |
| Tirzepatide | 43624-018 | Injection, solution | Drugs for further processing | August 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.